Literature DB >> 11302934

Biodistribution of 4-[(14)C]cholesterol-AmBisome following a single intravenous administration to rats.

R W Townsend1, A Zutshi, I Bekersky.   

Abstract

A biodistribution study of 4-[(14)C]cholesterol-AmBisome; a unilamellar liposomal preparation of amphotericin B was conducted to support a radiolabeled human study. The radioactive plasma concentration profile (as measured in microg-Eq/ml of cholesterol) was best fit to a sum of three exponentials that yielded alpha-, beta-, and gamma-half-life estimates of 3.0 +/- 0.3, 11.8 +/- 3.7, and 113.4 +/- 32.4 h, respectively. Clearance and the steady state volume of distribution were 4.9 +/- 0.2 ml/h/kg and 341 ml/kg. Recovery data collected up through 96 h demonstrated mass balance and indicated that although the elimination profile in both urine and feces were incomplete, the dominant route of elimination (<2% in urine versus 33% in feces) was feces, presumably via biliary excretion of intact liposome and/or cholesterol. The liver, spleen, and lungs, organs of the reticuloendothelial system known for their rapid uptake of liposomes, presented with the highest levels of radioactivity. Levels in the kidney were 15% of that found in the liver and lungs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302934

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Authors:  Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  Assessment of Uptake and Biodistribution of Radiolabeled Cholesterol in Mice Using Gavaged Recombinant Triglyceride-rich Lipoprotein Particles (rTRL).

Authors:  Anna Worthmann; Clara John; Joerg Heeren
Journal:  Bio Protoc       Date:  2018-07-05

3.  Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.

Authors:  J A Sánchez-Brunete; M A Dea; S Rama; F Bolás; J M Alunda; R Raposo; M T Méndez; S Torrado-Santiago; J J Torrado
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

4.  Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules.

Authors:  Shalini Asthana; Anil K Jaiswal; Pramod K Gupta; Vivek K Pawar; Anuradha Dube; Manish K Chourasia
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

5.  Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells.

Authors:  Zhen Zhao; Yuanke Li; Akshay Jain; Zhijin Chen; Hao Liu; Wei Jin; Kun Cheng
Journal:  Nanomedicine       Date:  2017-09-07       Impact factor: 5.307

6.  An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis.

Authors:  Tatiana G Ribeiro; Juçara R Franca; Leonardo L Fuscaldi; Mara L Santos; Mariana C Duarte; Paula S Lage; Vivian T Martins; Lourena E Costa; Simone O A Fernandes; Valbert N Cardoso; Rachel O Castilho; Manuel Soto; Carlos A P Tavares; André A G Faraco; Eduardo A F Coelho; Miguel A Chávez-Fumagalli
Journal:  Int J Nanomedicine       Date:  2014-11-19

Review 7.  Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B.

Authors:  Andreas H Groll; Bart J A Rijnders; Thomas J Walsh; Jill Adler-Moore; Russell E Lewis; Roger J M Brüggemann
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.